Search Results

You are looking at 1 - 10 of 141 items for :

  • "histopathology" x
Clear All
Full access

Harry S. Cooper

significance of microscopic invasive cancer in endoscopically removed polyps of the large bowel: clinical pathological study of 51 cases . Cancer 1983 ; 2 : 1691 – 1699 . 6. Morson BC Whiteway JE Jones EA . Histopathology and prognosis of

Full access

Tanner M. Johanns, Cole J. Ferguson, Patrick M. Grierson, Sonika Dahiya and George Ansstas

. Histopathology of tumor from patient 1, composed of mostly epithelioid glial cells (A; hematoxylin-eosin [HE] staining, original mag-nification x20) with focal endothelial hyperplasia (B, asterisk; HE staining, original magnification x20), prominent infiltrative

Full access

Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer and Miranda Hughes

Guidelines and debate among panel members about recent clinical trials. The topics include 1) intraperitoneal (IP) chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and

Full access

Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns and Miranda Hughes

subtypes may occur. The less common ovarian histopathologies (LCOHs) include carcinosarcomas (malignant mixed Müllerian tumors [MMMTs] of the ovary), clear cell carcinomas, mucinous carcinomas, grade 1 (low-grade) serous carcinomas/endometrioid epithelial

Full access

Jennifer Shih, Babar Bashir, Karen S. Gustafson, Mark Andrake, Roland L. Dunbrack, Lori J. Goldstein and Yanis Boumber

regions of 50 cancer-relevant genes, including EGFR, KRAS, BRAF , and ERBB2 ( HER2 ). Indeed, the timing Figure 2 Histopathology of adenocarcinoma in the lung. Fine-needle aspiration biopsy of the tumor in the lung shows adenocarcinoma (formalin

Full access

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng and Theresa L. Werner

be considered in treatment guidelines. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer discuss epithelial ovarian cancer (including borderline or low malignant potential) and less-common histopathologies

Full access

Emil Lou, Donna D'Souza and Andrew C. Nelson

inhibitors, such as cetuximab or panitumumab. 5 However, by pooling all KRAS mutations in the same category, are we performing the medical equivalent of throwing out Figure 3. Histopathology evaluation of the metastatic tumors. (A) Hematoxylin

Full access

Duke Comprehensive Cancer Center

Ovarian neoplasms consist of several histopathologic entities, and treatment depends on the specific tumor type. Epithelial ovarian cancer comprises most malignant ovarian neoplasms; however, other pathologic subtypes (such as less common ovarian histopathologies) must be considered. These guidelines discuss epithelial ovarian cancer as well as less common ovarian histopathologies, including germ cell neoplasms, mixed müllerian tumors of the ovary, and ovarian stromal tumors.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Liqin Zhu, Liyuan Li, Laura Hamel and Dolores Lopez-Terrada

, respectively. These HB PDOs displayed histopathology consistent with that of their parental tumors. When we tested the first group of 6 PDO lines to the 10 drugs included in recently opened COG AHEP1531 clinical trial for pediatric liver cancer, we found 2

Full access

Sumit Saini, Rishi Nayyar, Alpana Sharma and Prem Nath Dogra

& EpCam and negative for expression of CD45 was defined as a CTC. The number of CTC in pre and postoperative samples were compared and correlated to the final histopathology. Results: 32 patients were studied. No perforations were encountered. 4/32 (12